FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202789711> ?p ?o ?g. }

• W3202789711 endingPage "66" @default.
• W3202789711 startingPage "59" @default.
• W3202789711 abstract "Abstract Background The taxane cabazitaxel (CBZ) is a promising treatment for docetaxel-resistant castration-resistant prostate cancer (CRPC). However, the survival benefit with CBZ for patients with CRPC is limited. This study used screening tests for candidate drugs targeting CBZ-resistant-related gene expression and identified pimozide as a potential candidate for overcoming CBZ resistance in CRPC. Methods We established CBZ-resistant cell lines, DU145CR and PC3CR by incubating DU145 cells and PC3 cells with gradually increasing concentrations of CBZ. We performed in silico drug screening for candidate drugs that could reprogram the gene expression signature of a CBZ-resistant prostate cancer cells using a Connectivity Map. The in vivo effect of the drug combination was tested in xenograft mice models. Results We identified pimozide as a promising candidate drug for CBZ-resistant CRPC. Pimozide had a significant antitumor effect on DU145CR cells. Moreover, combination treatment with pimozide and CBZ had a synergic effect for DU145CR cells in vitro and in vivo. Microarray analysis identified AURKB and KIF20A as potential targets of pimozide in CBZ-resistant CRPC. DU145CR had significantly higher AURKB and KIF20A expression compared with a non-CBZ-resistant cell line. Inhibition of AURKB and KIF20A had an antitumor effect in DU145CR xenograft tumors. Higher expression of AURKB and KIF20A was a poor prognostic factor of TGCA prostate cancer cohort. CBZ-resistant prostate cancer tissues in our institution had higher AURKB and KIF20A expression. Conclusions Pimozide appears to be a promising drug to overcome CBZ resistance in CRPC by targeting AURKB and KIF20A ." @default.
• W3202789711 created "2021-10-11" @default.
• W3202789711 creator A5046347321 @default.
• W3202789711 creator A5072727806 @default.
• W3202789711 creator A5086644570 @default.
• W3202789711 creator A5090965553 @default.
• W3202789711 date "2021-09-30" @default.
• W3202789711 modified "2023-10-16" @default.
• W3202789711 title "Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening" @default.
• W3202789711 cites W1629666474 @default.
• W3202789711 cites W1924315434 @default.
• W3202789711 cites W1955107491 @default.
• W3202789711 cites W1980906844 @default.
• W3202789711 cites W1988377311 @default.
• W3202789711 cites W1990067517 @default.
• W3202789711 cites W1994034939 @default.
• W3202789711 cites W1999477673 @default.
• W3202789711 cites W2007742576 @default.
• W3202789711 cites W2023685223 @default.
• W3202789711 cites W2029980980 @default.
• W3202789711 cites W2039377776 @default.
• W3202789711 cites W2041503985 @default.
• W3202789711 cites W2052348324 @default.
• W3202789711 cites W2062533676 @default.
• W3202789711 cites W2069643337 @default.
• W3202789711 cites W2080439368 @default.
• W3202789711 cites W2094791588 @default.
• W3202789711 cites W2099582158 @default.
• W3202789711 cites W2109087158 @default.
• W3202789711 cites W2121604817 @default.
• W3202789711 cites W2123526148 @default.
• W3202789711 cites W2125247503 @default.
• W3202789711 cites W2134873805 @default.
• W3202789711 cites W2145193102 @default.
• W3202789711 cites W2153850465 @default.
• W3202789711 cites W2155444810 @default.
• W3202789711 cites W2155888201 @default.
• W3202789711 cites W2161112598 @default.
• W3202789711 cites W2292362441 @default.
• W3202789711 cites W2340534380 @default.
• W3202789711 cites W2508354247 @default.
• W3202789711 cites W2529944834 @default.
• W3202789711 cites W2573418691 @default.
• W3202789711 cites W2862473350 @default.
• W3202789711 cites W2897078879 @default.
• W3202789711 doi "https://doi.org/10.1038/s41391-021-00426-0" @default.
• W3202789711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34593983" @default.
• W3202789711 hasPublicationYear "2021" @default.
• W3202789711 type Work @default.
• W3202789711 sameAs 3202789711 @default.
• W3202789711 citedByCount "8" @default.
• W3202789711 countsByYear W32027897112021 @default.
• W3202789711 countsByYear W32027897112022 @default.
• W3202789711 countsByYear W32027897112023 @default.
• W3202789711 crossrefType "journal-article" @default.
• W3202789711 hasAuthorship W3202789711A5046347321 @default.
• W3202789711 hasAuthorship W3202789711A5072727806 @default.
• W3202789711 hasAuthorship W3202789711A5086644570 @default.
• W3202789711 hasAuthorship W3202789711A5090965553 @default.
• W3202789711 hasBestOaLocation W32027897111 @default.
• W3202789711 hasConcept C104317684 @default.
• W3202789711 hasConcept C121608353 @default.
• W3202789711 hasConcept C126322002 @default.
• W3202789711 hasConcept C143998085 @default.
• W3202789711 hasConcept C150903083 @default.
• W3202789711 hasConcept C207001950 @default.
• W3202789711 hasConcept C2775905019 @default.
• W3202789711 hasConcept C2777511904 @default.
• W3202789711 hasConcept C2777899217 @default.
• W3202789711 hasConcept C2778971682 @default.
• W3202789711 hasConcept C2780192828 @default.
• W3202789711 hasConcept C2781190966 @default.
• W3202789711 hasConcept C502942594 @default.
• W3202789711 hasConcept C530470458 @default.
• W3202789711 hasConcept C55493867 @default.
• W3202789711 hasConcept C71924100 @default.
• W3202789711 hasConcept C86803240 @default.
• W3202789711 hasConcept C98274493 @default.
• W3202789711 hasConceptScore W3202789711C104317684 @default.
• W3202789711 hasConceptScore W3202789711C121608353 @default.
• W3202789711 hasConceptScore W3202789711C126322002 @default.
• W3202789711 hasConceptScore W3202789711C143998085 @default.
• W3202789711 hasConceptScore W3202789711C150903083 @default.
• W3202789711 hasConceptScore W3202789711C207001950 @default.
• W3202789711 hasConceptScore W3202789711C2775905019 @default.
• W3202789711 hasConceptScore W3202789711C2777511904 @default.
• W3202789711 hasConceptScore W3202789711C2777899217 @default.
• W3202789711 hasConceptScore W3202789711C2778971682 @default.
• W3202789711 hasConceptScore W3202789711C2780192828 @default.
• W3202789711 hasConceptScore W3202789711C2781190966 @default.
• W3202789711 hasConceptScore W3202789711C502942594 @default.
• W3202789711 hasConceptScore W3202789711C530470458 @default.
• W3202789711 hasConceptScore W3202789711C55493867 @default.
• W3202789711 hasConceptScore W3202789711C71924100 @default.
• W3202789711 hasConceptScore W3202789711C86803240 @default.
• W3202789711 hasConceptScore W3202789711C98274493 @default.
• W3202789711 hasIssue "1" @default.
• W3202789711 hasLocation W32027897111 @default.

• next